IL89793A - Medicinal product for the treatment of infection with retrovirus and a method for its preparation - Google Patents

Medicinal product for the treatment of infection with retrovirus and a method for its preparation

Info

Publication number: IL89793A
Authority: IL; Israel
Prior art keywords: pharmaceutical composition; component; niruri; combination; administration
Prior art date: 1988-03-29

Application number

IL8979389A

Other languages

English (en)

Hebrew (he)

Other versions

IL89793A0 (en

Original Assignee

Fox Chase Cancer Center

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-03-29

Filing date

1989-03-29

Publication date

1994-02-27

1989-03-29 Application filed by Fox Chase Cancer Center filed Critical Fox Chase Cancer Center

1989-09-28 Publication of IL89793A0 publication Critical patent/IL89793A0/xx

1994-02-27 Publication of IL89793A publication Critical patent/IL89793A/en

Links

239000008194 pharmaceutical composition Substances 0.000 title claims description 25
238000000034 method Methods 0.000 title claims description 23
208000005074 Retroviridae Infections Diseases 0.000 title claims description 10
238000002360 preparation method Methods 0.000 title description 2
244000038594 Phyllanthus urinaria Species 0.000 claims description 45
102100034343 Integrase Human genes 0.000 claims description 26
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 26
230000002401 inhibitory effect Effects 0.000 claims description 17
241000700605 Viruses Species 0.000 claims description 15
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
241000713869 Moloney murine leukemia virus Species 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 10
241001430294 unidentified retrovirus Species 0.000 claims description 9
241000725303 Human immunodeficiency virus Species 0.000 claims description 8
241001130943 Phyllanthus <Aves> Species 0.000 claims description 6
238000007912 intraperitoneal administration Methods 0.000 claims description 5
241000714474 Rous sarcoma virus Species 0.000 claims description 4
239000003443 antiviral agent Substances 0.000 claims description 4
230000037396 body weight Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
238000003808 methanol extraction Methods 0.000 claims description 3
230000004083 survival effect Effects 0.000 claims description 2
230000000153 supplemental effect Effects 0.000 claims 3
238000001990 intravenous administration Methods 0.000 claims 2
238000007911 parenteral administration Methods 0.000 claims 2
238000003809 water extraction Methods 0.000 claims 1
239000000284 extract Substances 0.000 description 26
230000005764 inhibitory process Effects 0.000 description 18
241001465754 Metazoa Species 0.000 description 14
238000012360 testing method Methods 0.000 description 14
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
241000196324 Embryophyta Species 0.000 description 12
239000006286 aqueous extract Substances 0.000 description 11
230000000694 effects Effects 0.000 description 11
239000000825 pharmaceutical preparation Substances 0.000 description 10
238000003556 assay Methods 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
238000000605 extraction Methods 0.000 description 7
WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 6
239000000203 mixture Substances 0.000 description 6
108020004414 DNA Proteins 0.000 description 5
239000012531 culture fluid Substances 0.000 description 5
208000006454 hepatitis Diseases 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
241000894007 species Species 0.000 description 5
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 4
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 4
241000725618 Duck hepatitis B virus Species 0.000 description 4
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
239000013543 active substance Substances 0.000 description 4
230000000798 anti-retroviral effect Effects 0.000 description 4
231100000283 hepatitis Toxicity 0.000 description 4
239000002035 hexane extract Substances 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000002609 medium Substances 0.000 description 4
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 4
208000030507 AIDS Diseases 0.000 description 3
241000272525 Anas platyrhynchos Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
244000173207 Phyllanthus amarus Species 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000000463 material Substances 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
239000000401 methanolic extract Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000010076 replication Effects 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
229960002555 zidovudine Drugs 0.000 description 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
208000031886 HIV Infections Diseases 0.000 description 2
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
208000037357 HIV infectious disease Diseases 0.000 description 2
241000282412 Homo Species 0.000 description 2
241000598436 Human T-cell lymphotropic virus Species 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000002012 ayurvedic medicine Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007975 buffered saline Substances 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
229960005102 foscarnet Drugs 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
238000010166 immunofluorescence Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
239000000419 plant extract Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000000047 product Substances 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
238000005303 weighing Methods 0.000 description 2
WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 description 1
YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
206010011906 Death Diseases 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
102000000588 Interleukin-2 Human genes 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical group [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
229910021380 Manganese Chloride Inorganic materials 0.000 description 1
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical group Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
241000283923 Marmota monax Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
108091028043 Nucleic acid sequence Proteins 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
241001379470 Phyllanthus fraternus Species 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
206010042674 Swelling Diseases 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108020000999 Viral RNA Proteins 0.000 description 1
241001492404 Woodchuck hepatitis virus Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
244000309466 calf Species 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000002153 concerted effect Effects 0.000 description 1
230000001143 conditioned effect Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
239000002612 dispersion medium Substances 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
230000001882 diuretic effect Effects 0.000 description 1
208000002173 dizziness Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
201000006549 dyspepsia Diseases 0.000 description 1
206010014801 endophthalmitis Diseases 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
229960002963 ganciclovir Drugs 0.000 description 1
IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
239000003365 glass fiber Substances 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000011670 long-evans rat Methods 0.000 description 1
238000000464 low-speed centrifugation Methods 0.000 description 1
239000006166 lysate Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
229910052748 manganese Inorganic materials 0.000 description 1
239000011572 manganese Substances 0.000 description 1
239000011565 manganese chloride Substances 0.000 description 1
235000002867 manganese chloride Nutrition 0.000 description 1
239000002398 materia medica Substances 0.000 description 1
208000007106 menorrhagia Diseases 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
230000001177 retroviral effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 1
229960001099 trimetrexate Drugs 0.000 description 1
YFNGWGVTFYSJHE-UHFFFAOYSA-K trisodium;phosphonoformate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O.OP(O)(=O)C([O-])=O YFNGWGVTFYSJHE-UHFFFAOYSA-K 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
231100000397 ulcer Toxicity 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals

Landscapes

Health & Medical Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Alternative & Traditional Medicine (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Medical Informatics (AREA)
Botany (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Plant Substances (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

IL8979389A 1988-03-29 1989-03-29 Medicinal product for the treatment of infection with retrovirus and a method for its preparation IL89793A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/174,695 US4937074A (en)	1988-03-29	1988-03-29	Method of treating retrovirus infection

Publications (2)

Publication Number	Publication Date
IL89793A0 IL89793A0 (en)	1989-09-28
IL89793A true IL89793A (en)	1994-02-27

Family

ID=22637149

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8979389A IL89793A (en)	1988-03-29	1989-03-29	Medicinal product for the treatment of infection with retrovirus and a method for its preparation

Country Status (10)

Country	Link
US (1)	US4937074A (da)
EP (1)	EP0407452B1 (da)
JP (1)	JPH03505325A (da)
CN (1)	CN1037903A (da)
AU (1)	AU617068B2 (da)
DE (1)	DE68908701D1 (da)
DK (1)	DK234590D0 (da)
IL (1)	IL89793A (da)
WO (1)	WO1989009059A1 (da)
ZA (1)	ZA892308B (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH02270824A (ja) *	1989-04-13	1990-11-05	Snow Brand Milk Prod Co Ltd	逆転写酵素阻害剤
US5178865A (en) *	1990-06-19	1993-01-12	Cedars-Sinai Medical Center	Chinese herbal extracts in the treatment of hiv related disease in vitro
AU644669B2 (en) *	1990-06-19	1993-12-16	Cedars-Sinai Medical Center	Chinese herbal extracts in the treatment of hiv related disease
US5141923A (en) *	1990-12-31	1992-08-25	Immunology, Inc., A California Corporation	Methods for the treatment of retroviral infections
US5360714A (en) *	1992-08-28	1994-11-01	Fox Chase Cancer Center	Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
US5334525A (en) *	1992-08-28	1994-08-02	Fox Chase Cancer Center	Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
WO1996010649A1 (en) *	1994-09-30	1996-04-11	Southwest Foundation For Biomedical Research	Isolated human hepatitis b virus polymerase and uses thereof
BR9913333A (pt)	1998-08-25	2001-05-15	Univ Yale	Inibição e tratamento do vìrus da hepatite b e flavivìrus com helioxatina e seus análogos
DE19919585A1 (de)	1999-04-29	2000-12-07	Cmi Ag	Verwendung von Phyllanthus zur Behandlung von oxidativem Streß und anderen Symptomen
DE10030139A1 (de) *	2000-06-20	2002-01-10	Cmi Ag	Verwendung von Phyllanthusbesandteilen zur Behandlung oder Prophylaxe von Infekten durch Flaviviridae
EP1333848B1 (en) *	2000-10-06	2006-04-05	Phytrix AG	Phyllanthus-derived compounds for the prevention and/or treatment of diseases associated with a retrovirus
ATE275413T1 (de) *	2000-10-06	2004-09-15	Phytrix Ag	Verfahren zur herstellung von phyllanthusextrakten
DE10120627A1 (de) *	2001-04-26	2002-10-31	Cmi Ag	Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren
US20050129780A1 (en) *	2002-05-29	2005-06-16	Holcomb-Halstead Terri L.	Relief of aids symptoms
EP2116253A1 (en)	2008-05-07	2009-11-11	Phytrix JV, LLC	Novel phyllanthus extract
CN103435704A (zh) *	2013-08-26	2013-12-11	孟祥帅	一种豌豆淀粉的生产方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4673575A (en) *	1985-04-26	1987-06-16	Fox Chase Cancer Center	Composition, pharmaceutical preparation and method for treating viral hepatitus

1988
- 1988-03-29 US US07/174,695 patent/US4937074A/en not_active Expired - Lifetime
1989
- 1989-03-28 AU AU34133/89A patent/AU617068B2/en not_active Ceased
- 1989-03-28 EP EP89904470A patent/EP0407452B1/en not_active Expired - Lifetime
- 1989-03-28 DE DE89904470T patent/DE68908701D1/de not_active Expired - Lifetime
- 1989-03-28 WO PCT/US1989/001270 patent/WO1989009059A1/en not_active Ceased
- 1989-03-28 JP JP1504343A patent/JPH03505325A/ja active Pending
- 1989-03-29 IL IL8979389A patent/IL89793A/en not_active IP Right Cessation
- 1989-03-29 CN CN89101876A patent/CN1037903A/zh active Pending
- 1989-03-29 ZA ZA892308A patent/ZA892308B/xx unknown
1990
- 1990-09-28 DK DK234590A patent/DK234590D0/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
DE68908701D1 (de)	1993-09-30
DK234590A (da)	1990-09-28
WO1989009059A1 (en)	1989-10-05
JPH03505325A (ja)	1991-11-21
EP0407452A1 (en)	1991-01-16
DK234590D0 (da)	1990-09-28
CN1037903A (zh)	1989-12-13
EP0407452A4 (en)	1991-08-21
EP0407452B1 (en)	1993-08-25
US4937074A (en)	1990-06-26
IL89793A0 (en)	1989-09-28
ZA892308B (en)	1990-02-28
AU3413389A (en)	1989-10-16
AU617068B2 (en)	1991-11-14

Legal Events

Date	Code	Title	Description
2000-02-17	RH	Patent void

Publication	Publication Date	Title
US4937074A (en)	1990-06-26	Method of treating retrovirus infection
Lin et al.	1989	Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol
Sarin et al.	1987	Inhibition of replication of the etiologic agent of acquired immune deficiency syndrome (human T-lymphotropic retrovirus/lymphadenopathy-associated virus) by avarol and avarone
US5521161A (en)	1996-05-28	Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US5047435A (en)	1991-09-10	Antiviral compositions containing aromatic polycyclic diones and method for treating retrovirus infections
US6030980A (en)	2000-02-29	Agent for the treatment of infections
DE69032613T2 (de)	1999-02-25	Zusammensetzung und verfahren zur behandlung viraler infektionen
EP0199429A2 (en)	1986-10-29	Manufacture of a medicament for treating viral hepatitis
DE3881864T2 (de)	1993-09-30	Antivirale zusammensetzungen mit aromatischen polycyclischen dionen sowie methode zur behandlung retroviraler infektionen.
KR19990015612A (ko)	1999-03-05	황백피와 마타리 식물의 혼합추출물을 함유하는 c형 간염 치료제조성물
KR100239878B1 (ko)	2000-02-01	간질환 예방 및 치료용 생약조성물
KR101213599B1 (ko)	2012-12-18	데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 간기능 치료제 조성물
JPH09241157A (ja)	1997-09-16	リソスペルメートｂ含有肝臓保護作用医薬組成物
AU760967B2 (en)	2003-05-22	Herbal composition for the prophylaxis and treatment of AIDS
JP4121957B2 (ja)	2008-07-23	藍調製物、ならびにそのヒト免疫不全ウイルスの感染予防または治療における用途
Wang et al.	1999	Recent studies on Tripterygium wilfordii
JPH11209282A (ja)	1999-08-03	ベルゲニン及びその誘導体を有効成分とする肝機能改善剤
AU3423989A (en)	1989-10-16	Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
JP2857388B1 (ja)	1999-02-17	アカメガシワ樹皮のエキスを有効成分とする肝機能改善剤、肝機能改善飲料、及び肝機能改善茶
AU631989B2 (en)	1992-12-10	Novel application of 4-carbamoyl-1-beta-d-ribofuranosyl imidazolium-5-olate
KR100193216B1 (ko)	1999-06-15	황백피와 마타리 식물의 혼합 수추출물을 함유하는 후천성면역결핍증 치료제 조성물
KR20030064327A (ko)	2003-07-31	간염 치료제 및 예방제 또는 간보호제로 유용한 섬오갈피추출물
JPH07126180A (ja)	1995-05-16	発癌抑制剤
WO1989009055A1 (en)	1989-10-05	Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
CN120960294A (zh)	2025-11-18	红茴香或其提取物在制备抗猪流行性腹泻病毒药物中的应用